IGCIGC Pharma, Inc.

NYSE igcpharma.com


$ 0.39 $ 0.15 (36.61 %)    

Friday, 21-Jun-2024 15:21:30 EDT
QQQ $ 480.84 $ -1.29 (-0.27 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 0.55
$ 0.39
$ 0.00 x 0
$ 0.64 x 200
$ 0.39 - $ 0.39
$ 0.25 - $ 0.91
431,578
na
35.05M
$ 1.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-14-2024 12-31-2023 10-Q
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 07-07-2023 03-31-2023 10-K
5 02-14-2023 12-31-2022 10-Q
6 11-01-2022 09-30-2022 10-Q
7 08-05-2022 06-30-2022 10-Q
8 06-22-2022 03-31-2022 10-K
9 02-10-2022 12-31-2021 10-Q
10 10-29-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 06-14-2021 03-31-2021 10-K
13 02-16-2021 12-31-2020 10-Q
14 11-20-2020 09-30-2020 10-Q
15 08-19-2020 06-30-2020 10-Q
16 07-13-2020 03-31-2020 10-K
17 02-10-2020 12-31-2019 10-Q
18 11-06-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 06-14-2019 03-31-2019 10-K
21 02-12-2019 12-31-2018 10-Q
22 10-16-2018 09-30-2018 10-Q
23 08-03-2018 06-30-2018 10-Q
24 06-21-2018 03-31-2018 10-K
25 02-20-2018 12-31-2017 10-Q
26 11-17-2017 09-30-2017 10-Q
27 08-18-2017 06-30-2017 10-Q
28 07-14-2017 03-31-2017 10-K
29 02-21-2017 12-31-2016 10-Q
30 11-21-2016 09-30-2016 10-Q
31 08-16-2016 06-30-2016 10-Q
32 07-14-2016 03-31-2016 10-K
33 02-16-2016 12-31-2015 10-Q
34 11-13-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 07-14-2015 03-31-2015 10-K
37 02-12-2015 12-31-2014 10-Q
38 11-13-2014 09-30-2014 10-Q
39 08-14-2014 06-30-2014 10-Q
40 07-15-2014 03-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-reiterates-buy-on-igc-pharma-maintains-325-price-target

Ascendiant Capital analyst Edward Woo reiterates IGC Pharma (AMEX:IGC) with a Buy and maintains $3.25 price target.

 igc-pharma-publishes-study-in-european-society-of-medicine-for-impact-of-cyp2c9-genetic-polymorphism-on-pharmacokinetics-of-delta-9-tetrahydrocannabinol

-- Study Deepens Understanding of Treatments for Alzheimer's Patients, Enabling More Effective Treatments --

Core News & Articles

https://subscriber.politicopro.com/article/2024/05/justice-department-poised-to-post-plans-for-marijuana-reclassification-00158...

Core News & Articles

https://www.marijuanamoment.net/dea-appears-to-question-marijuanas-medical-value-despite-rescheduling-recommendation/ 

Core News & Articles

https://twitter.com/KevinSabet/status/1787569052782846142 

Core News & Articles

https://www.marijuanamoment.net/florida-gop-formally-opposes-marijuana-legalization-ballot-initiative-clearing-path-for-desanti...

Core News & Articles

https://www.wsj.com/finance/regulation/declassifying-cannabis-still-leaves-pot-stocks-in-limbo-26d417ec

Core News & Articles

https://www.marijuanamoment.net/schumer-says-dea-marijuana-rescheduling-decision-is-historic-but-he-remains-strongly-committed-...

 igc-pharma-announces-interim-results-for-igc-ad1-in-reducing-alzheimers-agitation-results-indicate-that-igc-ad1-clinically-reduced-agitation-compared-to-placebo

-Reuters

Core News & Articles

https://www.audacy.com/talk1370/news/business/cannabis-seizures-at-checkpoints-by-us-mexico-border-frustrates-state-authorized-...

 igc-pharma-says-cannabinoid-based-drug-candidate-provides-fast-relief-with-fewer-side-effects-for-alzheimers-associated-agitation

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest signifi...